Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
| ▸ | TPO | P07202 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960677 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1958856 | 0.82 | SMN1; SMN2 (0.46) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1962737 | 0.76 | SMN1; SMN2 (0.41) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL10699801 | 0.69 | KDM4E (0.68) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1958327 | 0.67 | MTNR1A (0.52) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL14205210 | 0.67 | KDM4E (0.68) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1945331 | 0.65 | KDM4E (0.64) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1460828 | 0.65 | ADORA2A (0.59) | ALDH1A1HPGDSMN1; SMN2MPOTPO | |
| Hydrochloric Acid SCHEMBL7028005 | 0.64 | MAPT (0.43) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1959299 | 0.63 | PDE1A (0.58) | KDM4EALDH1A1KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236951-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2012-08-07 | — | — | US | disclosed |
| EP-2332541-A1 | Use of thioxanthine derivatives as MPO inhibitors | AstraZeneca AB (SE) | 2011-06-15 | — | — | EP | disclosed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-7425560-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | disclosed |
| EP-1499613-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | KDM4E 3438/4885ALDH1A1 178/4885KMT2A 3549/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | KDM4E 3438/4885ALDH1A1 178/4885KMT2A 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.